Cited 18 times in
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2015-12-28T10:53:44Z | - |
dc.date.available | 2015-12-28T10:53:44Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138255 | - |
dc.description.abstract | BACKGROUND: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. METHODS: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. RESULTS: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). CONCLUSIONS: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1433~1437 | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Angiogenesis Inhibitors/adverse effects | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/ethnology* | - |
dc.subject.MESH | Carcinoma, Renal Cell/pathology | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/ethnology* | - |
dc.subject.MESH | Kidney Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/antagonists & inhibitors* | - |
dc.title | Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Y Wang | - |
dc.contributor.googleauthor | T K Choueiri | - |
dc.contributor.googleauthor | J L Lee | - |
dc.contributor.googleauthor | M H Tan | - |
dc.contributor.googleauthor | S Y Rha | - |
dc.contributor.googleauthor | S A North | - |
dc.contributor.googleauthor | C K Kollmannsberger | - |
dc.contributor.googleauthor | D F McDermott | - |
dc.contributor.googleauthor | D Y C Heng | - |
dc.identifier.doi | 10.1038/bjc.2014.28 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00406 | - |
dc.identifier.eissn | 1532-1827 | - |
dc.identifier.pmid | 24548864 | - |
dc.subject.keyword | sunitinib | - |
dc.subject.keyword | sorafenib | - |
dc.subject.keyword | ethnicity | - |
dc.subject.keyword | VEGF | - |
dc.subject.keyword | progression-free survival | - |
dc.subject.keyword | overall survival | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 110 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1433 | - |
dc.citation.endPage | 1437 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, Vol.110(6) : 1433-1437, 2014 | - |
dc.identifier.rimsid | 52342 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.